Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
Dox usually given max 6 cycles over less than 5 months. We should have several patients whose disease has stabilised and without really bad side effects for more than double that. Remember these are end of the road patients.
A number of patients remain on the three-weekly study at this time in several different cohorts.
Dox usually given max 6 cycles over less than 5 months. We should have several patients whose disease has stabilised and without really bad side effects for more than double that.
Patients can be dosed in parallel in the two-weekly dose escalation study and Avacta remains on track to begin the dose expansion efficacy study in the second half of 2024.
Even with the recent raise the huge majority of shares are held with retail. If a vote was pushed I doubt the recent share give away would protect them. It's not just the raise it's the awful comms, DX acquisitions, unrealistic and missed timelines etc. Anyway, see what RNSs land over the next month and explanation re 50p raise
Sod AS but the independent clinicians would not be recommending their patients continue to go into hospital to take AVA6000 if they did not believe it was helping. The fact that dox can stabilise or get rid of tumours over a period of less than 5 months and we are able to dose over double that (dose dependent) and these patients won't have the awful side effects it's exciting. Depending on what comes out of the wash over the next month AS and the CFO may have to go and I'm sure they'll need some positive to get the share price a lot higher and some solid reasons why the 50p raise to stop some shareholders forcing an EGM
You’re right, AS should be afforded the time to explain how we’ve ended up where we are. Hopefully something compelling as the recent raise absolutely shambolic. The trial strategy explained too. See what RNSs and interviews come at and after AACR.
Did you read my reply? There will be candidates there. I’m not a specialist recruitment consultant or work in the city but there will be some superb candaistes and the sooner they search (might be already) the better. Of course it takes time so the sooner the better and perhaps AS knows this and after 20 odd years it’s time to step aside. We’ll see. Because I have a view doesn’t mean I have a specific name in mind. That’s the job of the specialists. If you think AS is up to the job of taking this to £1bn market cap that’s your view. We can agree to disagree.
I no longer work in the city so aren’t in ‘the know’ as it were. There will be candidates who will likely need to lean on the science bods at Avacta and elsewhere but will have a lot more commercial nouse. Taking a £50-£100m market cap co to a £1bn+ is a different skill set which is why it’s not for everyone. AS has no doubt done very well but it seems obvious to me he’s not the man to take Avacta to the next level and beyond. Or at least lay the foundations to get to the next level as it’ll increase value and get on more of the radars we want. I really don’t think AS is thought of a serious player in the city and although the science and platforms are all important an experienced and commercial CEO is needed to create and sustain value at a higher end.
A good example is the founder of Abcam, Jonathan Milner who took it from £25m or so to £500m or so before stepping aside as he’d taken it as far as he could.
Would CC want to be CEO, does she has the experience? She’s based in the US I believe so that’s an issue. CC could do a superb job in current role and support a CEO who’s able to take us to the next few levels. It’s AS’ baby but sadly if he doesn’t realise he should move aside for the greater good it’ll have to be forced on him. New CEO of course integral in appointing a new CFO. I’d hope the chairman would lean on AS to do the right thing.
First and foremost regain momentum and hopefully AACR will do so and then regain trust and credibility with a new CEO and new approach especially managing comms, creating and sustaining shareholder value and ensure the current plan re 6000 the best route to market and I suspect the new approach will be.
chairman is meant to manage the bod and protect shareholders. he's failed miserably, no question. ceo hasn't a commercial bone in his body and given we're aim listed, have few analysts following us with a largely retail base and have quarterly conversions the comms is so bad it's negligent. an absolute **** show and a lot of it seems unnecessary. changes needed imo, defo ceo and cfo have to go and the chairman needs to either pull his finger out or leave too. a lot of disruption but a new ceo needed and that should be the priority and i assume do so after aacr
According to the chairman the beauty of AVA6000 is that is allows dox to target the stroma which many anthracyclines are unable to do.
Copied and pasted the below -
The tumor microenvironment is a dynamic composite of cells broadly categorized as multiple components of no-stroma and stroma cells, where tumor cells thrive. Stroma cells promote tumor growth, invasion, and metastasis by secreting multiple cytokines, chemokines and other growth factors, et al.
AVA6000, dox and other anthracyclines will be excreted and whether the TME at different rates depending on the patient. That’s obvious. One thing is for sure the biopsies showed the the mechanism of action working as it did preclinical with lots more dox in the tumour than in blood which is why no MTS was found.
BNN Breaking is a news website based in Hong Kong launched in 2022 by Indian-American entrepreneur Gurbaksh Chahal. It has been criticised for posting a number of misleading and inaccurate news stories, potentially using AI-driven content aggregation.
Funny JWBellamy keep asking the same question even though he's been told the BOD has loads of options so the buys were for perception more than anything. JWB, again, how large is your short? Given the frequency of your posts surely it's large.
Funny JWBellamy keep asking the same question even though he's been told the BOD has loads of options so the buys were for perception more than anything. JWB, again, how large is your short? Given the frequency of your posts surely it's large?
Perhaps we'll hear more on the 3 weekly read-out.
I think it's good to see plenty of sellers who are indeed flipping their new shares for 5% or so. Clear as many of them down here now and when positive RNSs land we are able to move on up. There'll always be profit taking but for me get rid of as many as possible now is best.
JWB I hold here and my average around 90p so I am on paper down a shed load although my investment decision had nowt to do with Myles' investment and nor should anyone's.
Are you still short here?
JWB with the incessant posting I hope your short is a large as very odd otherwise
The II shares are already in circluation so I assume they have fewer than 9m or so (3%)
Just look back at the science day deck and you will see what the targets were and what was achieved.